the whole object this page is drawn from, as JSON · Open JSON
{
"schema":"https://miscsubjects.com/schemas/jarticle.json",
"status":"published",
"slug":"tirzepatide-glp1-agonists",
"title":"tirzepatide glp1 agonists",
"kind":"standard",
"summary":"Evidence is being populated by Grok web",
"created":"2026-06-29T17:45:36.023Z",
"body": [
"## Overview\nEvidence is being populated by Grok web search."
],
"facts": {
"converted_from":"markdown",
"original_updated":"2026-06-29T17:45:54.298Z",
"register":"standard",
"category":null
},
"sources": [
{
"id":"s1",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/40746703/",
"title":"Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration",
"quote":"A dose-dependent tirzepatide was superior to placebo and GLP-1 RAs in weight reduction. However, the lean mass reduction and tolerability require further investigation.",
"summary":"2025 meta-analysis of 6 RCTs (6266 subjects) showing tirzepatide (5-15mg) superior for weight loss vs placebo/GLP-1 RAs; high-certainty for ≥15% loss.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:45:36.162Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"genesis",
"hash":"0bc10e667490a0d1de52db56c7f9bc6edd4628dab777683966ad8fb5aa31ffbe",
"quote_sha256":"72db5087da8d14daf80a7f4d743fcbdd784cb386875a3a4bb37bde5f1200bd5c"
},
{
"id":"s2",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/42119587/",
"title":"Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial",
"quote":"We evaluated the efficacy and safety of continuing tirzepatide at the maximum tolerated dose (MTD) or lowering the dose to 5 mg compared with placebo.",
"summary":"2026 Lancet phase 3 trial on tirzepatide for weight maintenance in obesity.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:45:36.162Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"0bc10e667490a0d1de52db56c7f9bc6edd4628dab777683966ad8fb5aa31ffbe",
"hash":"8f9696ced4d3722d12ef2047cdc36535115e6cec92eb6498ecc410a89fc2c0fc",
"quote_sha256":"c25f8fac32fb17d050812ae64d9aa2731b213814b3d1dcb82449b66184042246"
},
{
"id":"s3",
"type":"clinical_trial",
"url":"https://clinicaltrials.gov/study/NCT06820281",
"title":"Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes",
"quote":"This mechanistic study will define mechanisms by which GLP1-GIP co-agonism may uniquely provide clinical benefits in T1D during the fasting and fed states.",
"summary":"2025 mechanistic trial on tirzepatide (GLP-1/GIP agonist) effects in type 1 diabetes.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:45:36.162Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"8f9696ced4d3722d12ef2047cdc36535115e6cec92eb6498ecc410a89fc2c0fc",
"hash":"167a284b48b2506597dcd0895fe37a97fc5a85d7d4f10fc652f45ef99360643e",
"quote_sha256":"7481a04538375a8c400150f7221a401552551fe47a03c888c0be22cdf1ee5630"
},
{
"id":"s4",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/40353578/",
"title":"Tirzepatide as Compared with Semaglutide for the Treatment of Obesity",
"quote":"Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight.",
"summary":"2025 SURMOUNT-5 trial: tirzepatide superior to semaglutide for weight loss in obesity without diabetes.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:45:36.162Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"167a284b48b2506597dcd0895fe37a97fc5a85d7d4f10fc652f45ef99360643e",
"hash":"3fcae7a5d9dce8b01400f3fddfd4cf2af5d76d57cb7e347371a7489bb63d625b",
"quote_sha256":"63e1eed5a123b6cf41f50f80ab69ac8d518b5860e6383673d390255af30aec65"
},
{
"id":"s5",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/41264593/",
"title":"Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Clinical Trial",
"quote":"Among adults with type 1 diabetes and obesity, tirzepatide was superior to placebo for weight loss over 12 weeks.",
"summary":"2026 phase 2 trial showing tirzepatide benefits in T1D with obesity.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:45:36.162Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"3fcae7a5d9dce8b01400f3fddfd4cf2af5d76d57cb7e347371a7489bb63d625b",
"hash":"3d44a8cc318c688eecec61496d7e0d2383560fd7f27b5d7e4e7227a9900a2699",
"quote_sha256":"8384b1e0c2332883eefe85f7f066b3c11054aefed10e3a439dfd9f8bc718d481"
},
{
"id":"s6",
"type":"review",
"url":"https://pubmed.ncbi.nlm.nih.gov/41761267/",
"title":"Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis",
"quote":"These findings suggest that tirzepatide provides cardiovascular benefit at least comparable to established GLP-1RAs, supporting its emerging role in cardiovascular risk reduction in T2D.",
"summary":"Systematic review and network meta-analysis of RCTs showing tirzepatide reduces MACE, CV mortality, all-cause mortality, non-fatal MI and stroke vs placebo, comparable to GLP-1RAs.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:45:53.437Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"3d44a8cc318c688eecec61496d7e0d2383560fd7f27b5d7e4e7227a9900a2699",
"hash":"8ee4366358b7274f085aa6b39475f0e69642e72bd24b4f5825e4f569c83da422",
"quote_sha256":"c71a8969e3a72eacedcab1234ee5318708326d0c46790817d03880e1dc0279d2"
},
{
"id":"s7",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/42168641/",
"title":"Causes and consequences of discontinuation of GLP1RAs and tirzepatide",
"quote":"In this Review, we discuss common reasons for GLP1R agonist and tirzepatide discontinuation and examine available evidence related to potential cardiometabolic ...",
"summary":"Review on discontinuation reasons for GLP-1RAs including tirzepatide and cardiometabolic evidence.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:45:53.437Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"8ee4366358b7274f085aa6b39475f0e69642e72bd24b4f5825e4f569c83da422",
"hash":"0371dcd0b18e6afd6695db514160cfd9aa4c24c546e658dc2ae6a5321560e678",
"quote_sha256":"1cd36cc8c8fd9bb65e7cd12f7cfe564defbbe439eddc10ce30400c6859490ad6"
},
{
"id":"s8",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/41655764/",
"title":"Ocular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists",
"quote":"Among patients with T2D taking a GLP-1 RA, tirzepatide was associated with lower risks of retinal complications, need for vision-saving ...",
"summary":"Study finding lower retinal complication risks with tirzepatide vs other GLP-1 RAs in T2D patients.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:45:53.437Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"0371dcd0b18e6afd6695db514160cfd9aa4c24c546e658dc2ae6a5321560e678",
"hash":"f48a6b4930245e0cbba1fa071ffd6911cb87d527571210dc93b88f65ff1cae64",
"quote_sha256":"e2267988b0881dee4b9fb48270c8815169fa3610502baee18c512bba1e25efc1"
},
{
"id":"s9",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/41936548/",
"title":"Weight Loss With GLP-1 Agonists in Nondiabetic Adults",
"quote":"Tirzepatide, particularly at higher doses, provides the greatest weight reduction in adults without diabetes.",
"summary":"Analysis showing tirzepatide superior for weight loss in nondiabetic adults compared to other GLP-1 agonists.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:45:53.437Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"f48a6b4930245e0cbba1fa071ffd6911cb87d527571210dc93b88f65ff1cae64",
"hash":"d7ea3b96d9412a96a0034ce9dee3ef7ee725221cd2174c0d90daf51b66336bbd",
"quote_sha256":"71633aad767378b74c3588c27bf44226cfc77c84403b57c83537f1cf10c7bacb"
}
],
"type":"article",
"updated":"2026-10-08T11:49:30.728Z",
"version":1,
"hash":"cc205d147ba4417ec5e972bbbe2b1339e9921f4ede134b79c2aeb39a457a317c",
"theme":"https://miscsubjects.com/article-theme.json",
"styling": {
"scope":"shared",
"theme_ref":"https://miscsubjects.com/article-theme.json"
},
"page":"https://miscsubjects.com/a/tirzepatide-glp1-agonists",
"json":"https://miscsubjects.com/a/tirzepatide-glp1-agonists.json",
"markdown":"https://miscsubjects.com/a/tirzepatide-glp1-agonists.md",
"calls": [
{
"what":"this article as a page (no key)",
"method":"GET",
"url":"https://miscsubjects.com/a/tirzepatide-glp1-agonists",
"headers": {}
},
{
"what":"this article as its object (no key)",
"method":"GET",
"url":"https://miscsubjects.com/a/tirzepatide-glp1-agonists.json",
"headers": {}
},
{
"what":"this article as Markdown (no key)",
"method":"GET",
"url":"https://miscsubjects.com/a/tirzepatide-glp1-agonists.md",
"headers": {}
},
{
"what":"the object with its hash, drafts too",
"method":"GET",
"url":"https://miscsubjects.com/api/jarticles/tirzepatide-glp1-agonists",
"headers": {
"x-terminal-key":"<YOUR_TERMINAL_KEY>"
}
},
{
"what":"one piece and that piece’s hash",
"method":"GET",
"url":"https://miscsubjects.com/api/jarticles/tirzepatide-glp1-agonists/at?path=facts",
"headers": {
"x-terminal-key":"<YOUR_TERMINAL_KEY>"
}
},
{
"what":"grep: every key or value that matches, with the path to change it",
"method":"GET",
"url":"https://miscsubjects.com/api/jarticles/tirzepatide-glp1-agonists/grep?q=owner",
"headers": {
"x-terminal-key":"<YOUR_TERMINAL_KEY>"
}
},
{
"what":"change pieces (set, merge, delete, append, insert, move); if-match is the hash",
"method":"PATCH",
"url":"https://miscsubjects.com/api/jarticles/tirzepatide-glp1-agonists",
"headers": {
"x-terminal-key":"<YOUR_TERMINAL_KEY>",
"content-type":"application/json",
"if-match":"<hash from the read>"
},
"body": {
"ops": [
{
"op":"set",
"path":"facts.example",
"value":1
}
]
}
},
{
"what":"replace the whole object",
"method":"PUT",
"url":"https://miscsubjects.com/api/jarticles/tirzepatide-glp1-agonists",
"headers": {
"x-terminal-key":"<YOUR_TERMINAL_KEY>",
"content-type":"application/json",
"if-match":"<hash>"
},
"body": {
"slug":"tirzepatide-glp1-agonists",
"title":"…"
}
},
{
"what":"fetch every source, hash what came back and check the quote is in it",
"method":"POST",
"url":"https://miscsubjects.com/api/jarticles/tirzepatide-glp1-agonists/verify",
"headers": {
"x-terminal-key":"<YOUR_TERMINAL_KEY>",
"content-type":"application/json"
},
"body": {}
},
{
"what":"an Obsidian-style command",
"method":"POST",
"url":"https://miscsubjects.com/api/jarticles/cli",
"headers": {
"x-terminal-key":"<YOUR_TERMINAL_KEY>",
"content-type":"application/json"
},
"body": {
"command":"backlinks",
"file":"tirzepatide-glp1-agonists"
}
}
],
"entities": {
"tirzepatide-glp1-agonists": {
"id":"tirzepatide-glp1-agonists",
"label":"tirzepatide glp1 agonists",
"type":"standard",
"page":"https://miscsubjects.com/a/tirzepatide-glp1-agonists",
"json":"https://miscsubjects.com/a/tirzepatide-glp1-agonists.json"
}
},
"relationships": {
"upward": {
"total":0,
"offset":0,
"limit":50,
"items": [],
"next":null
},
"downward": {
"total":0,
"offset":0,
"limit":50,
"items": [],
"next":null
},
"sideways": {
"total":0,
"offset":0,
"limit":50,
"items": [],
"next":null
},
"references": {
"total":0,
"offset":0,
"limit":50,
"items": [],
"next":null
},
"referenced_by": {
"total":0,
"offset":0,
"limit":50,
"items": [],
"next":null
}
},
"hierarchy": {
"paths": [],
"order":"subject to parent to ancestor",
"complete":true,
"cycles": [],
"limits": {
"depth":12,
"objects":250
},
"unresolved_refs": []
},
"reference_contract": {
"canonical_id":"slug",
"entity_lookup":"entities[ref]; # resolves to this object via self_ref",
"self_ref":"tirzepatide-glp1-agonists",
"entity_fields":"page and json are canonical object links; source_url is the external source",
"directions": {
"upward":"Parents and collections containing this object; predicate distinguishes location from membership.",
"downward":"Objects naming this object as their parent, container or collection.",
"sideways":"Associations and objects sharing a direct parent.",
"references":"Objects referenced by this record.",
"referenced_by":"Published articles referencing this record."
},
"predicates": {
"part_of":"Declared parent hierarchy.",
"located_in":"Location asserted on this object.",
"associated_parcel":"Associated parcel, a separate object with its own jurisdiction and facts.",
"member_of":"Collection membership, not geographic containment.",
"included_in":"Editorial nesting, not geographic containment.",
"shares_parent":"Shares the identified parent; no other relationship is implied.",
"related_to":"An association with no more specific predicate recorded."
},
"scope":"Published article objects; Atlas inventories have their own counted, paged links. An association does not transfer facts or jurisdiction. An absent neighborhood means no neighborhood relationship is recorded."
},
"hash_spec": {
"algorithm":"sha256",
"encoding":"lowercase hexadecimal",
"scope":"stored record; hash is also the write concurrency token",
"included_keys": [
"body",
"created",
"facts",
"kind",
"schema",
"slug",
"sources",
"status",
"summary",
"title",
"type",
"updated",
"version"
],
"field_overrides": {
"schema":"jarticle/1"
},
"canonicalization":"Select included_keys from this response, apply field_overrides, recursively sort object keys using JavaScript Object.keys().sort(), retain array order, serialize primitives with JSON.stringify, join without whitespace, hash UTF-8 bytes.",
"updated_included":true,
"generated_fields":"All fields absent from included_keys are excluded. Relationship counts and theme references are generated and can change without changing the stored-record hash."
}
}